SEC Company Response from NRX Pharmaceuticals, Inc. (NRXP) (CIK 0001719406) (NRXP) — Nov 16, 2017
NRX Pharmaceuticals, Inc. (NRXP) (CIK 0001719406)
Date: Nov. 16, 2017 · CIK: 0001719406 · Accession: 0001654954-17-010786
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220947
Letter
VIA EDGAR Securities and Exchange Commission Re: Big Rock Partners Acquisition Corp. (the "Company") Registration Statement on Form S-1 (File No. 333-220947) (the "Registration Statement")
Dear Ms. Ravitz:
In connection with the Registration Statement on Form S-1 of Big Rock Partners Acquisition Corp., the undersigned, which is acting as the representative of the underwriters of the offering, hereby requests acceleration of the effective date and time of the Registration Statement to 12:00 P.M., Monday, November 20, 2017 or as soon thereafter as practicable, pursuant to Rule 461 of the Securities Act of 1933.
Very truly
yours,
EARLYBIRDCAPITAL,
INC.
Show Raw Text
CORRESP 1 filename1.htm Blueprint EARLYBIRDCAPITAL, INC. 366 Madison Avenue | 8th Floor New York, NY 10017 November 16, 2017 VIA EDGAR Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attn: Amanda Ravitz Re: Big Rock Partners Acquisition Corp. (the "Company") Registration Statement on Form S-1 (File No. 333-220947) (the "Registration Statement") Dear Ms. Ravitz: In connection with the Registration Statement on Form S-1 of Big Rock Partners Acquisition Corp., the undersigned, which is acting as the representative of the underwriters of the offering, hereby requests acceleration of the effective date and time of the Registration Statement to 12:00 P.M., Monday, November 20, 2017 or as soon thereafter as practicable, pursuant to Rule 461 of the Securities Act of 1933. Very truly yours, EARLYBIRDCAPITAL, INC. By: /s/ Steven Levine Name: Steven Levine Title: CEO